Global pharmaceutical company Lupin Limited has announced a licensing and supply agreement with OLIC (Thailand) Limited, a subsidiary of the prominent Japanese firm Fuji Pharma Co., Ltd. This partnership will see the marketing of Nextstellis (drospirenone and estetrol tablets) in Vietnam and the Philippines.
Nextstellis is a birth control pill combining drospirenone (DRSP) and estetrol (E4), designed for women of reproductive age to prevent pregnancy. Dr. Fabrice Egros, President of Corporate Development and Growth Markets at Lupin, expressed excitement about the collaboration, stating that the addition of Nextstellis to their Women’s Health portfolio underscores their commitment to expanding healthcare options globally.
As reported by Medical Dialogues, Fuji Pharma specializes in women’s health, offering a wide range of new and generic drugs addressing conditions such as infertility, dysmenorrhea, endometriosis, contraception, and menopausal disorders.
Lupin, headquartered in Mumbai, India, is a transnational pharmaceutical leader known for developing and commercializing a diverse array of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company operates in over 100 markets, including the U.S., India, South Africa, and across the Asia Pacific, Latin America, Europe, and the Middle East.